Search

Search Constraints

You searched for: Author/Creator Faber, Edgar

Search Results

1. A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Issue 2 (1st February 2016)

2. Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study. Issue 2 (28th January 2020)

3. Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. Issue 9 (23rd July 2013)

4. Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels. (21st February 2013)

5. First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter. (June 2019)

6. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. Issue 10 (31st August 2018)

7. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Issue 11 (14th September 2019)

8. Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT. Issue 12 (14th October 2020)

9. Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT. Issue 12 (14th October 2020)

10. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era. Issue 7 (July 2014)